

## SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with  
Kallikrein 7 (KLK7)

<130> BHC 04 01 027

<160> 5

<170> PatentIn version 3.2

<210> 1

<211> 969

<212> DNA

<213> Homo sapiens

<400> 1

```
ggatttccgg gctccatggc aagatccctt ctctgcccc tgcagatcct actgctatcc      60
ttagccttgg aaactgcagg agaagaagcc cagggtgaca agattattga tggcgcccca      120
tgtgcaagag gctcccaccc atggcagggtg gccctgctca gtggcaatca gctccactgc      180
ggagggcgccc tggatcaatga ggcgtgggtg ctccactgccg cccactgcaa gatgaatgag      240
tacaccgtgc acctggggcag tgatacgctg ggcgacagga gagctcagag gatcaaggcc      300
tcgaagtcac tccgccaccc cggctactcc acacagaccc atgttaatga cctcatgctc      360
gtgaagctca atagccaggc caggctgtca tccatgggtga agaaagtcag gctgcctccc      420
cgctgcgaac cccctggaac cacctgtact gtctccggct ggggcactac cagcagccca      480
gatgtgacct ttccctctga cctcatgtgc gtggatgtca agctcatctc ccccaggac      540
tgcacgaagg tttaacaagga cttactggaa aattccatgc tgtgcgctgg catccccgac      600
tccaagaaaa acgcctgcaa tgggtgactca gggggaccgt tgggtgtgcag aggtaccctg      660
caaggctctgg tgcctggggg aactttccct tgcggccaac ccaatgaccc aggagtctac      720
actcaagtgt gcaagttcac caagtggata aatgacacca tgaaaaagca tcgctaacgc      780
cacactgagt taattaactg tgtgcttcca acagaaaatg cacaggagtg aggacgccga      840
tgacctatga agtcaaattt gactttacct ttccctcaaag atatatttaa acctcatgcc      900
ctgttgataa accaatcaaa ttggtaaaga cctaaaacca aaacaaataa agaaacacaa      960
aacctcaa
```

<210> 2

<211> 253

<212> PRT

<213> Homo sapiens

<400> 2

- 2 -

Met Ala Arg Ser Leu Leu Leu Pro Leu Gln Ile Leu Leu Leu Ser Leu  
 1 5 10 15  
 Ala Leu Glu Thr Ala Gly Glu Glu Ala Gln Gly Asp Lys Ile Ile Asp  
 20 25 30  
 Gly Ala Pro Cys Ala Arg Gly Ser His Pro Trp Gln Val Ala Leu Leu  
 35 40 45  
 Ser Gly Asn Gln Leu His Cys Gly Gly Val Leu Val Asn Glu Arg Trp  
 50 55 60  
 Val Leu Thr Ala Ala His Cys Lys Met Asn Glu Tyr Thr Val His Leu  
 65 70 75 80  
 Gly Ser Asp Thr Leu Gly Asp Arg Arg Ala Gln Arg Ile Lys Ala Ser  
 85 90 95  
 Lys Ser Phe Arg His Pro Gly Tyr Ser Thr Gln Thr His Val Asn Asp  
 100 105 110  
 Leu Met Leu Val Lys Leu Asn Ser Gln Ala Arg Leu Ser Ser Met Val  
 115 120 125  
 Lys Lys Val Arg Leu Pro Ser Arg Cys Glu Pro Pro Gly Thr Thr Cys  
 130 135 140  
 Thr Val Ser Gly Trp Gly Thr Thr Thr Ser Pro Asp Val Thr Phe Pro  
 145 150 155 160  
 Ser Asp Leu Met Cys Val Asp Val Lys Leu Ile Ser Pro Gln Asp Cys  
 165 170 175  
 Thr Lys Val Tyr Lys Asp Leu Leu Glu Asn Ser Met Leu Cys Ala Gly  
 180 185 190  
 Ile Pro Asp Ser Lys Lys Asn Ala Cys Asn Gly Asp Ser Gly Gly Pro  
 195 200 205  
 Leu Val Cys Arg Gly Thr Leu Gln Gly Leu Val Ser Trp Gly Thr Phe  
 210 215 220  
 Pro Cys Gly Gln Pro Asn Asp Pro Gly Val Tyr Thr Gln Val Cys Lys  
 225 230 235 240  
 Phe Thr Lys Trp Ile Asn Asp Thr Met Lys Lys His Arg  
 245 250

&lt;210&gt; 3

&lt;211&gt; 19

&lt;212&gt; DNA

&lt;213&gt; artificial sequence

&lt;220&gt;

&lt;223&gt; forward primer

&lt;400&gt; 3

gcatccccga ctccaagaa

19

&lt;210&gt; 4

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> reverse primer

<400> 4

cagggtacct ctgcacacca a

21

<210> 5

<211> 24

<212> DNA

<213> artificial sequence

<220>

<223> probe

<400> 5

aacgcctgca atggtgactc aggg

24